Table 4

Cardiorespiratory, Muscular, and Metabolic Results at Baseline and After 3 Months of Testosterone Supplementation Therapy in Patients With Low (i.e., <12 nmol/l) and Normal Baseline Testosterone Levels

Low Testosterone Group (n = 12)Normal Testosterone Group (n = 19)
BeforeAfterBeforeAfter
Peak VO2, ml/kg/min11.1 ± 2.415.1 ± 2.014.3 ± 2.216.9 ± 1.7
VE/VCO2slope34.0 ± 7.229.8 ± 6.033.1 ± 6.129.0 ± 5.4
6MWT, m369.5 ± 98.2466.0 ± 104.7397.9 ± 100.4478.6 ± 93.2
MVC, Nm92.3 ± 18.1131.6 ± 21.2124.66 ± 15.3140.6 ± 21.2
PTmax, Nm73.8 ± 17.483.8 ± 12.374.0 ± 17.484.4 ± 11.3
HOMA-IR2.4 (1.9–2.8)1.9 (1.5–2.2)2.2 (1.8–2.5)1.8 (1.4–2.3)

Data are expressed as mean ± SD or as median (interquartile range) for HOMA-IR.

VE/VCO2= ventilation/carbon dioxide output; VO2= oxygen consumption; other abbreviations as in Tables 2 and 3.

  • Between groups differences;

  • within groups differences at p < 0.05.